Global Bubonic Plague Market, By Diagnosis (Blood Culture, Sputum Culture, Lymph Node Culture, Chest X-Ray), Treatment (Antibiotics, Vaccines), End-User (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The bubonic plague market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.90% in the above-mentioned research forecast period. Ongoing research and products under clinical trials are the factors for the growth of the bubonic plague market. Advance or severe form of bubonic plague can led to other plague known as pneumonic plague which affects the lungs which can drive the bubonic plague market growth.
Bubonic plague is a bacterial infection which is caused by the bite of the infected flea or insects. The bacterial infection involved is yersinia pestis. This bacterial infection enters into the lymphatic system and lymph nodes which gets inflamed and is painful. The inflamed portion is called the bubo that’s why the plague is known as bubonic plague. The advanced stage of the plague is that the lymph node may become the open sores which are filled with pus and the infection can spread to the lungs. Transmission from one human to other is rare and sometimes the rodent who is bitten by the flea gets infected and then can spread to human body.
Increase in prevalence and incidence of bubonic plague which is one of the major drivers for the bubonic plague market growth. Almost 80% of population from the United States were affected with bubonic plague. Recently, the cases of bubonic plague are about 1-17 cases per year. Increase in population living in the villages with no proper care of sanitation which leads to the growth of infected insects may increase the bubonic plague market growth. Increase in adoption of companion animals, awareness about the plague and initiatives taken by the organizations such as WHO has driven the growth of the bubonic plague market. Strict regulations for the approval of vaccines and complications related to the plague such as death after receiving the treatment, gangrene and meningitis which is rare may hamper the growth of the bubonic plague market.
This bubonic plague market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the bubonic plague market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Bubonic Plague Market Scope and Market Size
The bubonic plague market is segmented on the basis of diagnosis, treatment, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diagnosis, the bubonic plague market is segmented into blood culture, sputum culture, lymph node culture and chest X-ray.
- On the basis of treatment, the bubonic plague market is segmented into antibiotics and vaccines. Antibiotics are further segmented to ciprofloxacin (cipro), doxycycline (vibramycin), gentamicin (garamycin), levofloxacin (levaquin) and streptomycin. Vaccines are further segmented to plague, inactivated and whole cell (J07AK01).
- On the basis of end-user, the bubonic plague market is segmented to hospitals and others.
- On the basis of distribution channel, the bubonic plague market is segmented into hospital pharmacy, retail pharmacy and others
Global Bubonic Plague Market Country Level Analysis
Global bubonic plague market is analysed and market size information is provided by country, diagnosis, treatment, end-user and distribution channel as referenced above.
The countries covered in the bubonic plague market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share because of increasing number of patients with bubonic plague especially in the United States, increase in healthcare expenditure and adoption of companion animals. Europe holds the second largest share due to increase in patient population and market players.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The bubonic plague market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to bubonic plague market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the bubonic plague market in the growth period.
Competitive Landscape and Global Bubonic Plague Market Share Analysis
The bubonic plague market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global bubonic plague market.
The major players covered in the global bubonic plague market report are iBio, Inc., DynPort Vaccine Company LLC, Bayer Healthcare, Pfizer, Inc. and AstraZeneca among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.